GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Olema Pharmaceuticals inc (NAS:OLMA) » Definitions » Earnings Yield (Joel Greenblatt) %

Olema Pharmaceuticals (Olema Pharmaceuticals) Earnings Yield (Joel Greenblatt) % : -28.41% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Olema Pharmaceuticals Earnings Yield (Joel Greenblatt) %?

Olema Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was $385.66 Mil. Olema Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-109.70 Mil. Olema Pharmaceuticals's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2024 was -28.41%.

The historical rank and industry rank for Olema Pharmaceuticals's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

OLMA' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3333.33   Med: 0   Max: No Debt
Current: -39.68

During the past 6 years, the highest Earnings Yield (Joel Greenblatt) of Olema Pharmaceuticals was 10000.00%. The lowest was -3333.33%. And the median was 0.00%.

OLMA's Earnings Yield (Joel Greenblatt) % is ranked worse than
68.62% of 1418 companies
in the Biotechnology industry
Industry Median: -15.77 vs OLMA: -39.68

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Olema Pharmaceuticals's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Olema Pharmaceuticals Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Olema Pharmaceuticals's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Olema Pharmaceuticals Earnings Yield (Joel Greenblatt) % Chart

Olema Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial - -1.38 -80.65 104.17 -20.49

Olema Pharmaceuticals Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 263.16 -49.26 -25.45 -20.49 -28.41

Competitive Comparison of Olema Pharmaceuticals's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Olema Pharmaceuticals's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Olema Pharmaceuticals's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Olema Pharmaceuticals's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Olema Pharmaceuticals's Earnings Yield (Joel Greenblatt) % falls into.



Olema Pharmaceuticals Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Olema Pharmaceuticalss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-104.961/512.158984
=-20.49 %

Olema Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-109.70 Mil.



Olema Pharmaceuticals  (NAS:OLMA) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Olema Pharmaceuticals Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Olema Pharmaceuticals's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Olema Pharmaceuticals (Olema Pharmaceuticals) Business Description

Industry
Traded in Other Exchanges
N/A
Address
512, 2nd Street, 4th Floor, San Francisco, CA, USA, 94107
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.
Executives
Cyrus Harmon director, officer: Chief Technology Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Paradigm Biocapital Advisors Lp 10 percent owner 767 THIRD AVENUE, 17TH FLOOR, NEW YORK NY 10017
G. Walmsley Graham director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kovacs Shane William Charles officer: Ch. Operating & Financial Off. PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Naseem Zojwalla officer: Chief Medical Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Sean Bohen director, officer: President and CEO C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
David C. Myles officer: Chief Development Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Senai Asefaw 10 percent owner 767 THIRD AVENUE, 17TH FLOOR, NEW YORK CITY NY 10017
Paradigm Biocapital International Fund Ltd. 10 percent owner C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Biotechnology Value Fund L P 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Paradigm Biocapital Advisors Gp Llc 10 percent owner 767 THIRD AVENUE, 17TH FLOOR, NEW YORK CITY NY 10017
Kinney Horn officer: Chief Business Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Yi Larson director C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116